Lilly reports Foundayo data. Eli Lilly and Company stock costs EUR 1,021.90 ahead of results

Published on 10/02/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Foundayo showed 57.00 percent lower predicted diabetes risk at 72 weeks. Eli Lilly and Company stock was trading at EUR 1,021.90 on October 2, 2026 versus EUR 1,023.90.

Pop-Art-Comic im Lichtenstein-Stil: gelber Roboterarm hält irisierenden Siliziumwafer über zwei Reinraum-Techniker — Lam Research US5324571083 Pop Art Comic gelber Roboterarm transportiert irisierenden Silizium Wafer über Techniker, Illustration mit AI erstellt.

Eli Lilly and Company (ISIN US5324571083) was trading at EUR 1,021.90 at Lang & Schwarz on October 2, 2026 at 5:05 p.m. CEST, down 0.20 percent versus the prior close of EUR 1,023.90. On October 1, 2026, Eli Lilly reported that its oral GLP-1 medicine Foundayo was associated with a 57.00 percent reduction in predicted 10-year type 2 diabetes risk at the 17.2 mg dose after 72 weeks.

Foundayo adds measurable evidence

The company also reported an 18.00 percent reduction in predicted cardiovascular disease risk for the same dose. The result came from post-hoc analyses of the ATTAIN-1 Phase 3 study, which compared three Foundayo doses with placebo in adults with obesity or overweight and a weight-related medical condition.

The figures give Lilly another data point for its oral obesity-medicine strategy. They are modeled risk estimates rather than observed cardiovascular outcomes, so the commercial value depends on how regulators, prescribers and payers interpret the evidence.

Quarterly growth sets a high bar

Lilly's second-quarter 2026 results provide the financial baseline for that strategy. According to MarketBeat, revenue reached USD 22.97 billion, up 47.70 percent from the same quarter a year earlier, while earnings per share came to USD 8.38 versus a USD 6.40 consensus estimate.

That USD 1,311.96 average analyst target is distinct from the euro reference price. On September 28, 2026, MarketBeat reported that JPMorgan raised its target from USD 1,400.00 to USD 1,500.00 and maintained an Overweight rating. The target change signals confidence in Lilly's incretin growth, but the dollar target cannot be compared directly with the euro quote.

Next report arrives October 29

Eli Lilly lists its third-quarter 2026 earnings call for October 29, 2026. The date gives investors a near-term test of whether the company's rapid revenue expansion can continue while oral GLP-1 products move from clinical evidence toward broader commercial adoption.

Euro quote remains close to the prior close

The Lang & Schwarz price was EUR 1,021.90 on October 2, 2026 at 5:05 p.m. CEST, compared with a prior close of EUR 1,023.90 on October 1, 2026. The day change was minus 0.20 percent, leaving the euro quote broadly stable as the latest Foundayo data and the October earnings date set the next checkpoints for the stock. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Company stock.